Vergent Bioscience

Biotechnology
$52.1Mtotal raised · 6 rounds on record
$18.7Mlatest round · Venture round · Oct 2025 · 13 mo ago
$2Mgrants · 1 grant · CORDIS
1-10team · employees, estimated range

Overview

Vergent Bioscience’s lead compound, VGT-309, is a tumor-targeted fluorescent imaging agent intentionally designed to enable surgeons to see previously undetected or difficult-to-find tumors during surgery in real-time, ensuring all solid tumor tissue is removed.

Funding and backers

Total raised
$52.1M
6 rounds on record
Latest round
$18.7M
Venture round · Oct 2025 · 13 mo ago
Team
1-10
employees, estimated range
Grants
$2M
1 grant · CORDIS
The money's age
Due for its next round
13 months since the last round · not hiring
Momentum
0/100
no fresh signals
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Oct 7, 2025 Raised a round Venture round $18.7M · SEC Form D Feb 3, 2025 Took on debt financing $3.8M · SEC Form D Sep 8, 2022 Won a grant $2M · CORDIS Nov 8, 2021 Took on debt financing $1.2M · SEC Form D May 18, 2018 Raised a round Venture round $11.9M · SEC Form D
Funding rounds
RoundDateAmountInvestorsSource
Venture round Oct 2025 $18.7M — SEC Form D
Debt Financing Feb 2025 $3.8M — SEC Form D
Grant Sep 2022 $2M — CORDIS
Venture round Aug 2022 $21.5M — SEC Form D
Debt Financing Nov 2021 $1.2M — SEC Form D
Venture round May 2018 $11.9M — SEC Form D
Registers and programsofficial lists and records that name the company
Legal entity Vergent Bioscience, Inc. SEC Form D
Founders and leadersfrom filings, registers and the company's site
John Santini Jr.Executive Officer, DirectorSEC Form D
Jeffrey YureckoExecutive OfficerSEC Form D
Investors in similar startupsfunds that back the companies most like this one
Y Combinator
backs Clear Gene
General Catalyst
backs Waypoint Bio
DCVC
backs Shennon Biotechnologies
Draper Associates
backs Current Surgical
Hummingbird Ventures
backs Waypoint Bio
NFX
backs TwoStep
Similar startupsby what they do, their industry and backers
TwoStep11-50 employees
TwoStep Therapeutics. Developing tumor-targeted therapies with broad applicability across solid tumors.
Waypoint Bio11-50 employees
Waypoint Bio is a biotechnology company pioneering the next generation of cell therapies for solid tumors.
Current Surgical11-50 employees · 6 roles
Surgery Reinvented - Current Surgical targets early-stage solid tumors in areas where traditional surgical techniques fail.
SonoClearFounded 2019 · 1-10 employees
SonoClear AS develops an acoustic contrast fluid to remove noise in ultrasound images, used during brain tumor surgery to guide tumor…
Resolute ScienceVenture round $250k · 2 yr ago · Founded 2020
Developing a novel class of cancer therapeutics for solid tumors.
Shennon BiotechnologiesVenture round $12M · 1 mo ago · 201-500 employees
Precision Immunotherapies for Solid Tumors Built on Functional Biology at the Single-Cell Level.

Financials

Total raised
$59M
Latest round
Venture - Series Unknown
Funding rounds
6
Funding rounds
Round Announced Amount
Venture - Series Unknown 2025 $18.7M Details
Debt Financing 2025 $3.8M Details
Grant 2022 $2M Details
Venture - Series Unknown 2022 $21.5M Details
Debt Financing 2021 $1.2M Details
Venture - Series Unknown 2018 $11.9M Details

People

John Santini Jr.
Executive Officer, Director
SEC Form D
Jeffrey Yurecko
Executive Officer
SEC Form D
Douglas Kohrs
Director
SEC Form D
Raymond Wong
Director
SEC Form D
Bobby Helmedag
Director
SEC Form D
Anita Watkins
Director
SEC Form D
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data

Offices

Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Minneapolis United States
HQ
1-10 est. staff
5810 West 78th Street, Minneapolis, MN, 55439-2602, US
company site